841 related articles for article (PubMed ID: 16227993)
1. NKCC1 transporter facilitates seizures in the developing brain.
Dzhala VI; Talos DM; Sdrulla DA; Brumback AC; Mathews GC; Benke TA; Delpire E; Jensen FE; Staley KJ
Nat Med; 2005 Nov; 11(11):1205-13. PubMed ID: 16227993
[TBL] [Abstract][Full Text] [Related]
2. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Dzhala VI; Brumback AC; Staley KJ
Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
[TBL] [Abstract][Full Text] [Related]
3. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.
Kahle KT; Staley KJ
Neurosurg Focus; 2008 Sep; 25(3):E22. PubMed ID: 18759624
[TBL] [Abstract][Full Text] [Related]
4. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
5. Differences in cortical versus subcortical GABAergic signaling: a candidate mechanism of electroclinical uncoupling of neonatal seizures.
Glykys J; Dzhala VI; Kuchibhotla KV; Feng G; Kuner T; Augustine G; Bacskai BJ; Staley KJ
Neuron; 2009 Sep; 63(5):657-72. PubMed ID: 19755108
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.
Dzhala V; Staley KJ
CNS Neurosci Ther; 2015 Feb; 21(2):173-80. PubMed ID: 25495911
[TBL] [Abstract][Full Text] [Related]
7. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
Cleary RT; Sun H; Huynh T; Manning SM; Li Y; Rotenberg A; Talos DM; Kahle KT; Jackson M; Rakhade SN; Berry G; Jensen FE
PLoS One; 2013; 8(3):e57148. PubMed ID: 23536761
[TBL] [Abstract][Full Text] [Related]
8. Astrocytic NKCC1 inhibits seizures by buffering Cl
Nguyen TD; Ishibashi M; Sinha AS; Watanabe M; Kato D; Horiuchi H; Wake H; Fukuda A
Epilepsia; 2023 Dec; 64(12):3389-3403. PubMed ID: 37779224
[TBL] [Abstract][Full Text] [Related]
9. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1.
Kahle KT; Barnett SM; Sassower KC; Staley KJ
J Child Neurol; 2009 May; 24(5):572-6. PubMed ID: 19406757
[TBL] [Abstract][Full Text] [Related]
10. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Johne M; Käufer C; Römermann K; Gailus B; Gericke B; Löscher W
Epilepsia; 2021 Jun; 62(6):1460-1471. PubMed ID: 33955541
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Wang S; Zhang XQ; Song CG; Xiao T; Zhao M; Zhu G; Zhao CS
Neuroscience; 2015 Feb; 286():203-15. PubMed ID: 25463517
[TBL] [Abstract][Full Text] [Related]
12. Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
Sivakumaran S; Maguire J
Epilepsia; 2016 Feb; 57(2):222-32. PubMed ID: 26659482
[TBL] [Abstract][Full Text] [Related]
13. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
14. Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits.
Wang DD; Kriegstein AR
Cereb Cortex; 2011 Mar; 21(3):574-87. PubMed ID: 20624842
[TBL] [Abstract][Full Text] [Related]
15. Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus.
Nardou R; Ben-Ari Y; Khalilov I
J Neurophysiol; 2009 Jun; 101(6):2878-88. PubMed ID: 19297515
[TBL] [Abstract][Full Text] [Related]
16. Thermodynamic regulation of NKCC1-mediated Cl- cotransport underlies plasticity of GABA(A) signaling in neonatal neurons.
Brumback AC; Staley KJ
J Neurosci; 2008 Feb; 28(6):1301-12. PubMed ID: 18256250
[TBL] [Abstract][Full Text] [Related]
17. Chloride cotransporter NKCC1 inhibitor bumetanide protects against white matter injury in a rodent model of periventricular leukomalacia.
Jantzie LL; Hu MY; Park HK; Jackson MC; Yu J; Maxwell JR; Jensen FE
Pediatr Res; 2015 Apr; 77(4):554-62. PubMed ID: 25585037
[TBL] [Abstract][Full Text] [Related]
18. NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility.
Wang F; Wang X; Shapiro LA; Cotrina ML; Liu W; Wang EW; Gu S; Wang W; He X; Nedergaard M; Huang JH
Brain Struct Funct; 2017 Apr; 222(3):1543-1556. PubMed ID: 27586142
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Brandt C; Nozadze M; Heuchert N; Rattka M; Löscher W
J Neurosci; 2010 Jun; 30(25):8602-12. PubMed ID: 20573906
[TBL] [Abstract][Full Text] [Related]
20. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Welzel B; Schmidt R; Kirchhoff L; Gramer M; Löscher W
Epilepsy Behav; 2023 Feb; 139():109057. PubMed ID: 36586153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
